<i>In Silico</i> Screening of GC-MS Identified Phytochemicals from <i>Ziziphus oenoplia</i> (L.) Mill Leaves Extract Against Key Parkinson’s Disease Targets

Background: Parkinson’s disease (PD) is the second most common neurodegenerative disease, which causes α-synuclein aggregation, neuroinflammation, mitochondrial dysfunction, and kinase dysregulation leading to motor and non-motor symptoms. Plant-based compounds hold a superior role for multi-target action on PD pathogenesis, offering safety, alleviating side effects like dyskinesia and hallucinations caused by current PD drugs, and also providing synergistic potential over conventional single-target therapies. Aim: The purpose of this study was to investigate the anti-Parkinsonian activity of Ziziphus oenoplia (L.) Mill against key pathological targets in the Nrf2 (Nuclear factor erythroid 2-related factor 2) pathway by computational docking. Methods: From GC-MS(Gas chromatography-mass spectrometry) data, the thirteen phytochemical compounds from Ziziphus oenoplia (ZO) were docked against PD proteins such as Glycogen synthase kinase- 3β (GSK-3β), Kelch-like ECH-associated protein 1 (KEAP1), Leucine-rich repeat kinase 2 (LRRK2), Nuclear factor kappa B (NFκB), and α-synuclein against Levodopa as a standard compound using AutoDock Vina. Furthermore, ADMET analysis was done to assess the drug likeness, pharmacokinetic, and toxicity profile of the phytoconstituents using SwissADME and ProTox-3.0 tools. Results: Hydroxydehydrostevic acid emerged as the top performer against Levodopa in PD targets. The most notable binding energies are -10.58 kcal/mol for KEAP1, -9.71 kcal/mol for NFκB, and -9.61 kcal/mol across the GSK- 3β target. Conclusion: This is a preliminary computational study, and additional in vitro (e.g., SH-SY5Y neuronal cells for neuroprotection, cytotoxicity, and antioxidant assays) and in vivo (MPTP- or 6-OHDA-induced animal models) studies are needed before clinical translation to demonstrate the efficacy of hydroxydehydrostevic acid and to support its progression as a lead compound beyond Levodopa symptom control. Major Findings: Hy

View article page

Download PDF